Translating Patent Innovation into Clinical Practice: Two Decades of Therapeutic Advancements in Dysbiosis Management DOI Creative Commons
Fabiana D’Urso, Federica Paladini, Alessandro Miraglia

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 1064 - 1064

Published: May 3, 2025

Dysbiosis, characterized by a microbial imbalance, particularly within the gut microbiota, has emerged as significant health concern linked to various diseases. This study analyzed 8097 patent documents from The Lens database (2005–2024) examine global innovation trends in dysbiosis management. filings showed exponential growth, peaking at 1222 2022, with United States leading publications (4361 documents). analysis revealed three primary clusters: bacterial-based therapeutics (44.8% of patents), specific therapeutic applications (27.6%), and diagnostic methods (15.9%). disease associations predominantly included inflammatory conditions, infections, cancer. classifications highlighted focus on probiotic development microbiota modulation. surge activity since 2014 correlates advances DNA sequencing technology growing recognition dysbiosis’s role human health. provides valuable insights into evolving landscape microbiome future directions for

Language: Английский

NMR spectroscopy combined with chemometrics for quality assessment of common vegetable oils: A review DOI
Tao Shi,

Tenghui Dai,

Tao Zhang

et al.

Trends in Food Science & Technology, Journal Year: 2025, Volume and Issue: unknown, P. 104889 - 104889

Published: Jan. 1, 2025

Language: Английский

Citations

1
Identification of a dual-function peptide for the detection and haematopoietic potency assessment of type I collagen hydrolysates DOI Creative Commons

Guiya Deng,

Jiajun Wang, C Men

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 7(1)

Published: Feb. 26, 2025

Abstract Type I collagen hydrolysate with haematopoietic activity has shown tremendous potential for application in the functional food fields. The identification of peptide to ensure efficiency foods remains challenging because vast combinatorial short peptides from hydrolysates. In present study, we identified a novel marker (the I-1 peptide, GAAGLpGPK, p: hydroxyproline) type capabilities via theoretical sequence analysis and computational prediction activity. was increase survival rate stem cells following injury induced by 5-fluorouracil (5-FU), increasing 65.40 105.28%, thereby exhibiting significant More importantly, mechanism underlying analogous activate JAK/STAT signalling pathway mediated granulocyte‒macrophage colony‒stimulating factor. On this basis, high-precision method detection hydrolysates developed using (relative standard deviation = 1.57%). This study not only provides perspectives exploration but also offers new methodology controlling bioactivity collagen-based products. Graphical

Language: Английский

Citations

0
Application of curcuminoids in inflammatory, neurodegenerative and aging conditions - Pharmacological potential and bioengineering approaches to improve efficiency DOI Creative Commons
Ricardo Lagoa, Rajan Logesh,

Cristiana Violante

et al.

Biotechnology Advances, Journal Year: 2025, Volume and Issue: unknown, P. 108568 - 108568

Published: March 1, 2025

Language: Английский

Citations

0
Enhancing human gut health: Global innovations in dysbiosis management DOI Creative Commons
Reda El Boukhari, Maima Matin, Latifa Bouissane

et al.

iMeta, Journal Year: 2025, Volume and Issue: unknown

Published: April 13, 2025

Language: Английский

Citations

0
Exploring nutritional supplement use for Countering respiratory tract infections through an X (formerly Twitter)-based survey DOI Creative Commons
Rajeev K. Singla, Himel Mondal, Shailja Singla

et al.

Current Research in Biotechnology, Journal Year: 2025, Volume and Issue: unknown, P. 100282 - 100282

Published: April 1, 2025

Language: Английский

Citations

0
Translating Patent Innovation into Clinical Practice: Two Decades of Therapeutic Advancements in Dysbiosis Management DOI Creative Commons
Fabiana D’Urso, Federica Paladini, Alessandro Miraglia

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 1064 - 1064

Published: May 3, 2025

Dysbiosis, characterized by a microbial imbalance, particularly within the gut microbiota, has emerged as significant health concern linked to various diseases. This study analyzed 8097 patent documents from The Lens database (2005–2024) examine global innovation trends in dysbiosis management. filings showed exponential growth, peaking at 1222 2022, with United States leading publications (4361 documents). analysis revealed three primary clusters: bacterial-based therapeutics (44.8% of patents), specific therapeutic applications (27.6%), and diagnostic methods (15.9%). disease associations predominantly included inflammatory conditions, infections, cancer. classifications highlighted focus on probiotic development microbiota modulation. surge activity since 2014 correlates advances DNA sequencing technology growing recognition dysbiosis’s role human health. provides valuable insights into evolving landscape microbiome future directions for

Language: Английский

Citations

0